Mepitiostane
Mepitiostane is an ethylestrenol ether and a synthetic, orally active androgen and anabolic steroid (AAS) that is used in the treatment of breast cancer. It is marketed under the brand name Thioderon. Mepitiostane is a prodrug of ethylestrenol, meaning it is metabolically converted into ethylestrenol within the body. This conversion is necessary for its activity, as ethylestrenol is the active form of the drug.
Medical Uses
Mepitiostane is primarily used in the treatment of breast cancer in women. Its effectiveness in this application is attributed to its ability to reduce estrogen levels in the body, which can help to slow the growth of estrogen-sensitive cancer cells.
Pharmacology
Mechanism of Action
As an androgen and anabolic steroid, mepitiostane's mechanism of action involves its conversion to ethylestrenol, which then exerts anabolic and androgenic effects. These effects are mediated through the activation of the androgen receptor (AR), leading to various physiological and pharmacological outcomes. In the context of breast cancer, the reduction in estrogen levels is a key therapeutic effect.
Pharmacokinetics
Mepitiostane is administered orally. Upon ingestion, it is converted into ethylestrenol, its active metabolite. The pharmacokinetics of mepitiostane, including its absorption, distribution, metabolism, and excretion, are closely tied to those of ethylestrenol.
Adverse Effects
Like other androgens and anabolic steroids, mepitiostane can cause a range of adverse effects. These may include virilization in women, hepatotoxicity, alterations in lipid profiles, and changes in libido. The severity and occurrence of these side effects can vary based on the dosage and duration of treatment.
Contraindications
Mepitiostane is contraindicated in patients with known hypersensitivity to the drug or its components. It is also contraindicated in individuals with prostate cancer, as androgens can accelerate the growth of prostate cancer cells. Pregnant and breastfeeding women should avoid using mepitiostane due to potential risks to the fetus or infant.
See Also
References
<references/>
-
Mepitiostane
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian

